A5035755221- Acute Myeloid Leukemia Research
- Circular RNAs in diseases
- Pulmonary Hypertension Research and Treatments
- Retinoids in leukemia and cellular processes
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Sepsis Diagnosis and Treatment
- Cell death mechanisms and regulation
- COVID-19 Clinical Research Studies
- Chronic Myeloid Leukemia Treatments
- Cancer-related molecular mechanisms research
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- MicroRNA in disease regulation
- Kruppel-like factors research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
Medical University of Graz
2019-2023
Ludwig Boltzmann Institute for Lung Vascular Research
2023
Abstract Background Chronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic malignancy that arises from stem and progenitor cells (HSPCs). Patients with CMML are frequently treated epigenetic therapeutic approaches, in particular the hypomethylating agents (HMAs), azacitidine (Aza) decitabine (Dec). Although HMAs believed to mediate their efficacy via re-expression of hypermethylated tumor suppressors, knowledge about relevant HMA targets scarce. As silencing tumor-suppressive...
Immune cell recruitment, endothelial barrier disruption, and platelet activation are hallmarks of lung injuries caused by COVID-19 or other insults which can result in acute respiratory distress syndrome (ARDS). Basement membrane (BM) disruption is commonly observed ARDS, however, the role newly generated bioactive BM fragments mostly unknown. Here, we investigate endostatin, a fragment protein collagen XVIIIα1, on ARDS associated cellular functions such as neutrophil integrity, aggregation...
RAS-signaling mutations induce the myelomonocytic differentiation and proliferation of hematopoietic stem progenitor cells. Moreover, they are important players in development myeloid neoplasias. RAF kinase inhibitor protein (RKIP) is a negative regulator RAS-signaling. As RKIP loss has recently been described RAS-mutated acute leukemia, we now aimed to analyze its role RAS-driven leukemogenesis. Therefore, initially analyzed expression during human murine observed that it high cells...